We thrive on diversity.
Our management and business development teams encompass a rich mix of backgrounds, experiences and skills. Passionate scientists, chemists, biochemists, biologists, computational chemists, and DMPK experts, work together to make Sygnature the partner of choice, the expert provider of drug discovery services who will do everything to make your project succeed.
Filter by:
Dr Simon Hirst
Chief Executive Officer
Prof Andy Black
Non-executive Chairman
Dr Paul Clewlow
Non-executive Director
Dr Jonathan Williams
Chief Operating Officer
Mrs Victoria Tabiner
Chief Financial Officer
Mr Kevin Keck
Investment Director
Mr Barry Robinson
Investment Director
Dr Paul Overton
Chief Commercial Officer
Who We Are
Sygnature Discovery prides itself on offering a unique, high-quality, distinctive and tailored integrated drug discovery service to our clients. Our mission is to be admired for the science we do,…
Company History
Since 2004 Sygnature Discovery has been offering high-quality drug discovery services and providing guidance and support to clients for the discovery and development of novel medicines. The once small company…